scout
|Videos|August 25, 2017

Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME